With an A1C of 11.3 % and a random glucose of 378 mg/dL, normal cholesterol, HDL, LDL, VLDL, triglycerides now 170 mg/dL, GFR 114 mL/min/1.73 m² and normal liver function, should I initiate insulin therapy?

Yes, Initiate Insulin Therapy Immediately

With an A1C of 11.3% and random glucose of 378 mg/dL, insulin therapy is mandatory and should be started without delay. 1, 2

Rationale for Immediate Insulin Initiation

Your patient meets absolute criteria for insulin therapy based on current American Diabetes Association guidelines:

• A1C > 10% (86 mmol/mol) is an absolute indication for insulin initiation 1, 2
• Random glucose ≥ 300 mg/dL further mandates insulin therapy 2
• This degree of hyperglycemia poses immediate risk for microvascular complications, particularly diabetic nephropathy given the already elevated glucose exposure 3

The concern about kidney damage at these glucose levels is well-founded—chronic hyperglycemia is the strongest risk factor for diabetic nephropathy, and cells in the kidney do not require insulin for glucose entry, making them directly vulnerable to ambient hyperglycemia 3

Recommended Insulin Regimen

Starting Basal Insulin

Begin with basal insulin at 10 units daily or 0.1–0.2 units/kg/day using a long-acting analog (glargine, detemir, or degludec) 2:

• Long-acting analogs (U-100 glargine, detemir) reduce hypoglycemia risk compared to NPH insulin 3
• Longer-acting formulations (U-300 glargine, degludec) provide even lower nocturnal hypoglycemia risk 3
• Administer once daily at a consistent time 2

Titration Protocol

Increase basal insulin by 2 units every 3 days until fasting plasma glucose reaches individualized target (typically 80–130 mg/dL) 2:

• Monitor fasting glucose daily to guide titration 2
• If hypoglycemia occurs without obvious cause, reduce dose by 10–20% 2
• Recheck A1C in 3 months to assess response 1

Anticipate Need for Prandial Insulin

Given the severity of hyperglycemia (A1C 11.3%), basal insulin alone will likely be insufficient 3, 1:

• If A1C remains above goal after basal optimization, add a single prandial insulin dose (4 units or 10% of basal dose) before the largest meal 3, 2
• Use rapid-acting insulin analogs (aspart, lispro, glulisine) to minimize hypoglycemia risk 1
• Progress to full basal-bolus regimen (prandial insulin with each meal) if needed 3, 2

Critical Safety Measures

Hypoglycemia Prevention

• Prescribe a glucagon emergency kit at insulin initiation 1, 2
• Educate on recognition and treatment of hypoglycemia 4
• Warning symptoms may be blunted in patients with long diabetes duration or on beta-blockers 4

Renal Considerations

With GFR 114 mL/min/1.73 m², kidney function is currently normal, but:

• Insulin requirements decrease as renal function declines—monitor closely and adjust doses if GFR falls 4
• Hypoglycemia risk increases with renal impairment 2

Glucose Monitoring

• Implement self-monitoring of blood glucose at least 4 times daily (fasting and pre-meals) 1
• Consider continuous glucose monitoring (CGM) as standard of care for intensive insulin therapy 1

Diabetes Self-Management Education

Immediate referral to diabetes self-management education and support (DSMES) is essential 1:

• Insulin injection technique and device use 4
• Carbohydrate counting for future prandial insulin dosing 1
• Recognition and management of hypo- and hyperglycemia 4
• Sick-day management and dose adjustment 4

Lipid Management Context

The improved lipid profile (normal cholesterol, HDL, LDL, VLDL; triglycerides down to 170 mg/dL from 244 mg/dL) is encouraging 2. Insulin therapy may further improve the lipid profile:

• Insulin normalizes cholesterol synthesis in poorly controlled type 2 diabetes 5
• Improved glycemic control typically reduces triglycerides and increases HDL 6, 7
• Continue current lipid management while initiating insulin 2

Common Pitfalls to Avoid

• Do not delay insulin initiation while attempting to optimize oral agents—A1C > 10% mandates insulin 1, 2
• Avoid therapeutic inertia—reassess every 3 months and intensify therapy if A1C remains above goal 2
• Do not mix or dilute insulin detemir (Levemir) with other insulins—this alters pharmacokinetics 4
• Watch for over-basalization (bedtime-to-morning glucose differential ≥50 mg/dL, recurrent hypoglycemia)—this signals need for prandial rather than more basal insulin 3, 2

Target A1C Goal

Aim for A1C < 7% in most adults, which reduces microvascular complications 3, 1:

• The relationship between A1C and microvascular risk is curvilinear—greatest benefit comes from reducing very high A1C (11.3%) to moderate levels 3
• Adjust target based on hypoglycemia risk, life expectancy, and comorbidities 3
• With modern insulin analogs and glucose monitoring, tight control is achievable with lower hypoglycemia risk 3